These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29626845)

  • 1. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.
    Gupta M; Patel HD; Schwen ZR; Tran PT; Partin AW
    BJU Int; 2019 Feb; 123(2):252-260. PubMed ID: 29626845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study.
    Qin X; Han C; Zhang H; Dai B; Zhu Y; Shen Y; Zhu Y; Shi G; Ye D
    World J Surg Oncol; 2015 May; 13():172. PubMed ID: 25943443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.
    Jang TL; Patel N; Faiena I; Radadia KD; Moore DF; Elsamra SE; Singer EA; Stein MN; Eastham JA; Scardino PT; Lin Y; Kim IY; Lu-Yao GL
    Cancer; 2018 Oct; 124(20):4010-4022. PubMed ID: 30252932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
    JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer.
    Sarkar RR; Bryant AK; Parsons JK; Ryan ST; Karim Kader A; Kane CJ; McKay RR; Sandhu A; Murphy JD; Rose BS
    Eur Urol Oncol; 2019 Sep; 2(5):584-588. PubMed ID: 31411995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
    Herlemann A; Cowan JE; Washington SL; Wong AC; Broering JM; Carroll PR; Cooperberg MR
    Eur Urol; 2024 Jun; 85(6):565-573. PubMed ID: 37858454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefit.
    Heesterman BL; Aben KKH; van den Bergh ACM; van der Voort van Zyp JRN; Bokhorst LP
    Urol Oncol; 2024 Aug; 42(8):245.e9-245.e18. PubMed ID: 38724349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in management of lymph node positive prostate cancer after radical prostatectomy within a statewide quality improvement consortium.
    Triner D; Daignault-Newton S; Singhal U; Sessine M; Dess RT; Caram MEV; Borza T; Ginsburg KB; Lane BR; Morgan TM;
    Urol Oncol; 2024 Jul; 42(7):220.e1-220.e8. PubMed ID: 38570271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.
    Karnes RJ; Sharma V; Choeurng V; Ashab HA; Erho N; Alshalalfa M; Trock B; Ross A; Yousefi K; Tsai H; Zhao SG; Tosoian JJ; Haddad Z; Takhar M; Chang SL; Spratt DE; Abdollah F; Jenkins RB; Klein EA; Nguyen PL; Dicker AP; Den RB; Davicioni E; Feng FY; Lotan TL; Schaeffer EM
    Clin Cancer Res; 2018 Aug; 24(16):3908-3916. PubMed ID: 29760221
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.
    Shore ND; Moul JW; Pienta KJ; Czernin J; King MT; Freedland SJ
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):192-201. PubMed ID: 37679602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
    Hearn JWD; Xie W; Nakabayashi M; Almassi N; Reichard CA; Pomerantz M; Kantoff PW; Sharifi N
    JAMA Oncol; 2018 Apr; 4(4):558-562. PubMed ID: 29049492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer.
    Stranne J; Brasso K; Brennhovd B; Johansson E; Jäderling F; Kouri M; Lilleby W; Meidahl Petersen P; Mirtti T; Pettersson A; Rannikko A; Thellenberg C; Akre O
    Scand J Urol; 2018; 52(5-6):313-320. PubMed ID: 30585526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying low cancer-specific mortality risk lymph node-positive radical prostatectomy patients.
    Barletta F; Tappero S; Morra S; Incesu RB; Cano Garcia C; Piccinelli ML; Scheipner L; Tian Z; Gandaglia G; Stabile A; Mazzone E; Terrone C; Longo N; Tilki D; Chun FKH; de Cobelli O; Ahyai S; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    J Surg Oncol; 2024 Jun; 129(7):1305-1310. PubMed ID: 38470523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer.
    Holmes L; Chan W; Jiang Z; Ward D; Essien EJ; Du XL
    Cancer Control; 2009 Apr; 16(2):176-85. PubMed ID: 19337204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting current National Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis.
    Garg H; Dursun F; Alsayegh F; Wang H; Wu S; Liss MA; Kaushik D; Svatek RS; Mansour AM
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):244-251. PubMed ID: 36641534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
    Anderson-Carter I; Posielski N; Liou JI; Khemees TA; Downs TM; Abel EJ; Jarrard DF; Richards KA
    Urol Oncol; 2019 Feb; 37(2):130-137. PubMed ID: 30528885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection.
    Tiruye T; O'Callaghan M; FitzGerald LM; Moretti K; Jay A; Higgs B; Kichenadasse G; Caughey G; Roder D; Beckmann K
    Clin Genitourin Cancer; 2024 Apr; 22(2):599-609.e2. PubMed ID: 38369388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of chemotherapy in the definitive management of high risk prostate cancer.
    Ferris MJ; Liu Y; Ao J; Zhong J; Abugideiri M; Gillespie TW; Carthon BC; Bilen MA; Kucuk O; Jani AB
    Urol Oncol; 2018 Nov; 36(11):475-487. PubMed ID: 30309766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of androgen deprivation therapy for metastatic prostate cancer in older men.
    Keating NL; O'Malley AJ; McNaughton-Collins M; Oh WK; Smith MR
    BJU Int; 2008 May; 101(9):1077-83. PubMed ID: 18190632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local Therapy on Clinically Lymph Node-positive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yaow CYL; Lee HJ; Teoh SE; Chong RIH; Ng TK; Tay KJ; Ho H; Law YM; Tuan J; Yuen J; Chen K
    Eur Urol Oncol; 2024 Jun; 7(3):355-364. PubMed ID: 37730526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.